SLU-PP-332
Small-molecule oestrogen-related receptor (ERR) agonist used in nuclear-receptor research.
Prepared to order · approx. 7 days + Royal Mail Tracked 24
SKU BP-SLU332-5 · ≥99% (see COA) · Lyophilised powder
SLU-PP-332 overview
SLU-PP-332 is a synthetic small molecule (not a peptide) reported as a pan-ERR agonist. It is supplied as a solid for in-vitro research.
SLU-PP-332 research background
Evidence status: Findings summarised here come from published cell-culture and animal research only; no controlled human studies were identified. They are not established effects in humans, have not been evaluated by the MHRA, and are provided for scientific context only. This product is supplied strictly for laboratory research and is not for human or veterinary use.
Established research
Peer-reviewed published findings, with referencesOverview & discovery history
- SLU-PP-332 is a synthetic small-molecule agonist of the oestrogen-related receptors (ERRα/β/γ), developed by T. Burris and colleagues. It is not a peptide [1].
Chemical identity
Identity values are confirmed per lot on the certificate of analysis. Salt/counter-ion form (e.g. acetate or TFA) is stated on the COA where applicable.
Mechanisms investigated
- ERRα-dependent gene programme: in a muscle cell line it increased mitochondrial function and respiration. In mice it induced an ERRα-specific aerobic-exercise gene programme [1].
Research areas & model types
Human clinical research status
Safety observations reported in studies
- No human safety data exist.
Known limitations
- The evidence is preclinical only, from a small number of groups.
Storage & handling for laboratory use
Store at −20 °C. Protect from light.
Store lyophilised material sealed at −20 °C or below, protected from light and moisture. Allow the vial to equilibrate to room temperature before opening to limit condensation.
- Allow the sealed vial to reach room temperature before opening to limit condensation.
- Any solutions should be prepared only for in-vitro laboratory work under your own validated protocol; aliquoting limits repeated freeze–thaw cycles.
- Handle with standard laboratory PPE in line with your risk assessment and the Safety Data Sheet (SDS). Britpep does not provide preparation or administration guidance.
Emerging & theoretical
Unconfirmed — hypotheses & ongoing researchThese are unconfirmed hypotheses and early-stage lines of enquiry, not established effects. Not evaluated by the MHRA. Not for human or veterinary use.
Hypotheses proposed by researchers
- Researchers have proposed ERR agonists as 'exercise mimetics' and as candidates for metabolic and heart-failure research [1][5].
Open scientific questions
- What are the relative contributions of ERRα, β and γ?
Preprints: none included (no relevant preprint could be verified). Anecdotal, user-reported or social-media material is deliberately excluded.
References
- Billon C, Sitaula S, Banerjee S et al.. Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity. ACS Chem Biol. 2023. PubMed 36988910 · doi:10.1021/acschembio.2c00720
- Möller T, Krug O, Thevis M. In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential. Rapid Commun Mass Spectrom. 2026. PubMed 41588687 · doi:10.1002/rcm.70039
- Avliyakulov NK, Sobolevsky T, Ahrens E. Analysis and Identification of In Vitro Metabolites of Exercise Mimetic SLU-PP-332 ERRα/β/γ Agonist for Doping-Control Purposes. Drug Test Anal. 2026. PubMed 41688415 · doi:10.1002/dta.70035
- Billon C, Schoepke E, Avdagic A et al.. A Synthetic ERR Agonist Alleviates Metabolic Syndrome. J Pharmacol Exp Ther. 2024. PubMed 37739806 · doi:10.1124/jpet.123.001733
- Xu W, Billon C, Li H et al.. Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function. Circulation. 2024. PubMed 37961903 · doi:10.1161/CIRCULATIONAHA.123.066542
- Wang XX, Myakala K, Libby AE et al.. Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney. Am J Pathol. 2023. PubMed 37717940 · doi:10.1016/j.ajpath.2023.07.008
Every reference was checked against PubMed (NCBI) before publication. Summaries describe published research only and are not claims of any effect in humans or animals.
Certificates of analysis
[No batch COA published yet. The certificate for each lot will be listed here and in the COA checker before release.]
Related research compounds
Browse similar compounds: Mitochondrial & metabolic biochemistry research compounds or the full catalogue.